Microbot Medical, Inc. Common Stock (MBOT) is a publicly traded Healthcare sector company. As of May 21, 2026, MBOT trades at $1.74 with a market cap of $119.55M and a P/E ratio of -6.02. MBOT moved +0.00% today. Year to date, MBOT is -16.75%; over the trailing twelve months it is -33.59%. Its 52-week range spans $0.86 to $4.67. Analyst consensus is buy with an average price target of $8.75. Rallies surfaces MBOT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Microbot Medical Q2 Revenue Surpasses Q1 as Accounts Double Post Full Release: Microbot Medical recorded its first-quarter 2026 revenue from a Limited Market Release and reports mid-Q2 revenue exceeding total Q1 results. Accounts more than doubled post-Full Market Release, with six states now using LIBERTY for procedures from robotic PAE to Y-90 liver radioembolization.
| Metric | Value |
|---|---|
| Price | $1.74 |
| Market Cap | $119.55M |
| P/E Ratio | -6.02 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.67 |
| 52-Week Low | $0.86 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-13.14M |
| Gross Margin | 0.00% |
2 analysts cover MBOT: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.75.